Literature DB >> 4053429

Cardiac amyloidosis: combined use of two-dimensional echocardiography and electrocardiography in noninvasive screening before biopsy.

C A Sivaram, B I Jugdutt, R W Amy, C A Basualdo, M Haraphongse, T K Shnitka.   

Abstract

Cardiac amyloidosis (CA) presenting with intractable congestive heart failure, electrocardiographic (ECG) normal or low voltage, and conduction or rhythm disturbances, is rapidly fatal. During life, CA often mimics other cardiomyopathies so that definitive diagnosis depends on demonstration of amyloid on myocardial biopsy. On two-dimensional echocardiography (2-D echo), nonspecific features, such as increased ventricular wall thicknesses, predominant diastolic dysfunction, and diffuse myocardial "sparkling," are consistently found in CA. The combined presence of these 2-D echo features and normal or low voltage on ECG is highly suggestive of CA, allows differentiation from other cardiomyopathies, and might be useful in noninvasive screening before myocardial biopsy.

Entities:  

Mesh:

Year:  1985        PMID: 4053429     DOI: 10.1002/clc.4960081004

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Stiff heart syndrome.

Authors:  Sandeep Arora; Anju Arora; Ravinder P S Makkar; Amitabh Monga
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

2.  Embolic infarction associated with cardiac amyloidosis.

Authors:  Kyung-Hee Cho; Yong Mee Cho; Jong S Kim
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

3.  Is technetium-99 m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis?

Authors:  A Hartmann; J Frenkel; R Hopf; R P Baum; G Hör; M Schneider; M Kaltenbach
Journal:  Int J Card Imaging       Date:  1990

4.  A patient with cardiac amyloidosis presenting a rapid increase in technetium-99m-hydroxymethylene diphosphonate accumulation.

Authors:  T Kobayashi; M Sekiya; Y Fujiwara; T Sumimoto; H Matsuoka; M Hamada; K Hiwada
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.